SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug ‘SNB-101’ on Gastric Cancer.

SEONGNAM, South Korea, Dec. 24, 2025 /PRNewswire/ — SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gastroesophageal junction cancer) to SNB-101 (API: SN-38) which is a polymer nanoparticle drug under phase 1b/2 clinical trial for small cell lung cancer. SNB-101 […]